Nasdaq
華爾街日報BROOMFIELD, Colo., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain today provided a comprehensive corporate update, including financial results and strategic progress as the Company enters 2026 advancing its proprietary Nociscan platform.
Read more at globenewswire.comAclarion Provides 2025 Update and 2026 Corporate Outlook
Barchart·01/08/2026 05:00:00
語音播報
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.